Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

2cureX ApS. (6/8/10). "Press Release: 2cureX Announces Issuance of Final Patent Completing the Protection of the ChemoCellomics Technology". Copenhagen.

Region Region Europe
Organisation Organisation 2cureX ApS
Products Product ChemoCellomics® technology
  Product 2 2CX400 (2cureX)
Persons Person Thastrup, Ole (2cureX 200612–201108– CEO + co-founder + co-owner)
  Person 2 Jessen, Timm-Heinrich (Topas Therapeutics 201510– Managing Director before Bionamics + Scienamics + Evotec OAI)

2cureX is pleased to announce that a second patent providing a complete protection of 2cureX's core ChemoCellomics® has been issued (EP1761783). To obtain as broad a coverage of the invention as possible two patent application were originally filed on the same day. It is a pleasure to see that both applications now have issued in full which provides a strong basis for 2cureX to finalize its first product, 2CX400 said Ole Thastrup, CEO of 2cureX.

The patents cover integration of chemistry and cells on any solid support. The chemistry can for example be large chemical libraries synthesized directly on the support or it can be collections of approved drugs. These libraries can then be interrogated for their influence on the associated cells. These cells can be of mammalian origin (e.g. patient cells) or they can be parasites or microorganisms. 2cureX is focusing its own development efforts toward bringing a cancer treatment selection technology to the market; but will at the same time investigate licensing opportunities outside the company's business scope.

"2cureX is pushing hard to move its first product towards clinical testing in colorectal cancer patients. When committing resources and establishing partnerships to fulfil such endeavor it is important for us to know that the technology is effectively protected" said Timm Jessen, CBO of 2cureX.


Ole Thastrup Tel: +45 45822036
Chief Executive Officer e-mail:
Timm Jessen Tel: +49 (4315) 606 448
Chief Business Officer e-mail:

About 2cureX

o 2cureX is a Danish life science company that was spun-out of Carlsberg in 2006
o 2cureX develops a technology for individualised treatment of patients with solid cancers
o 2cureX is engaged in a comprehensive network of technical and clinical partners to exploit the
ChemoCellomics® technology

Record changed: 2015-08-10


Picture [LSUS] – The Business Web Portal 650x65px

More documents for 2cureX ApS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 650x65px

» top